1. Pink Sheet
  2. >>Agency Leadership

AAM Departures Lead To Change Of Chair For IGBA

Trio Of Executives Leave US Association, Including IGBA Chair For 2023

 
• By Dave Wallace

The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.

Revolving Doors Executives Blurred
Three executives have left the AAM, leading the IGBA to seek a new chair • Source: Shutterstock

Three senior executives at the Association for Accessible Medicines have seen their positions eliminated at the industry body as a result of the latest budgetary measures deployed by the US generics and biosimilars association.

The three affected roles are those of Allen Goldberg, the AAM’s senior vice-president for communications; Erik Komendant, the association’s senior vice-president of government affairs; and Jonathan Kimball,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.